Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 13, 2026 09:00 ET | Source: Oncolytics Biotech, Inc.

Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial

Oncolytics announced more than 20 patients pre-identified for REO 033 colorectal cancer trial and scheduled Type D meeting with the FDA.
July 02, 2026 06:00 ET | Source: Treos Bio Corp.

Treos Bio Presents New Translational Data Showing PolyPEPI1018 Plus Anti-PD-L1 Immunotherapy Remodels the Tumor Immune Microenvironment in MSS Colorectal Cancer

LONDON and BOSTON and BUDAPEST, Hungary, July 02, 2026 (GLOBE NEWSWIRE) -- Treos Bio, a clinical-stage biotechnology company developing off-the-shelf and personalized active cancer immunotherapies...
June 25, 2026 08:00 ET | Source: Lyell Immunopharma, Inc

Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

SOUTH SAN FRANCISCO, Calif., June 25, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen...
June 16, 2026 09:00 ET | Source: Oncolytics Biotech, Inc.

Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044

Oncolytics Biotech announced that the USPTO has issued a new patent broadly protecting the proprietary manufacturing process for pelareorep into 2044.
June 09, 2026 06:00 ET | Source: Treos Bio Corp.

TREOS Bio Presents New PEPI Technology Data at EACR 2026, Including Six-Year Cancer-Free Outcome in MSS Metastatic Colorectal Cancer (mCRC)

LONDON and BOSTON and BUDAPEST, Hungary, June 09, 2026 (GLOBE NEWSWIRE) -- Treos Bio, a clinical-stage company developing off-the-shelf and personalized active cancer immunotherapies, today...
June 08, 2026 06:00 ET | Source: Lyell Immunopharma, Inc

Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion

Gastrointestinal prophylaxis reduced Grade ≥ 2 diarrhea/colitis from 55% without prophylaxis to 10% with prophylaxisThe maximum tolerated dose has not yet been determinedNo difference is observed in...
June 02, 2026 09:00 ET | Source: Oncolytics Biotech, Inc.

Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer

Oncolytics Biotech announced the appointment of Steve Glover to its Board of Directors and the promotion of John McAdory to Chief Operating Officer.
June 01, 2026 09:00 ET | Source: Oncolytics Biotech, Inc.

Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches

Oncolytics announced data demonstrating evidence of greater anti-tumor activity with pelareorep in combination with RAS inhibitor modalities.
June 01, 2026 08:00 ET | Source: Lyell Immunopharma, Inc

Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026

SOUTH SAN FRANCISCO, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen...
May 15, 2026 09:49 ET | Source: BCC Research LLC

AI and Advanced Diagnostics Transform Cancer Detection Market Amid Rising Healthcare Investment

How chronic disease prevalence, infectious disease testing, AI investment, personalized medicine and regulatory change are shaping the diagnostics industry